Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Serum metabolic biomarkers for synucleinopathy conversion in isolated REM sleep behavior disorder

  • Xicoy Cortada, Helena
  • Tolosa, Eduardo
  • Serradell, Mònica
  • Gaig, Carles
  • Vila Bover, Miquel
  • Laguna Tuset, Ariadna
  • Vilas, Dolores
Neurodegeneració; Malaltia de Parkinson; Marcadors predictius, Neurodegeneración; Enfermedad de Parkinson; Marcadores predictivos, Neurodegeneration; Parkinson's disease; Predictive markers, Isolated rapid eye movement (REM) sleep behavior disorder (iRBD) is a prodromal stage of Lewy-type synucleinopathies (LTS), which can present either with an initial predominant parkinsonism (Parkinson’s disease (PD)) or dementia (dementia with Lewy bodies (DLB)). To provide insights into the underlying pathogenic mechanisms, the lipoprotein and protein glycosylation profile of 82 iRBD patients, collected before and/or after their conversion to an overt LTS, and 29 matched control serum samples were assessed by nuclear magnetic resonance (NMR) spectroscopy. Data were statistically analyzed to identify altered metabolites and construct predictive models. Univariant analysis detected no differences between iRBD patients with an LTS compared to controls. However, significant differences were found when the analysis distinguished between iRBD patients that manifested initially predominant parkinsonism (pre-PD) or dementia (pre-DLB). Significant differences were also found in the analysis of paired iRBD samples pre- and post-LTS diagnosis. Predictive models were built and distinguished between controls and pre-DLB patients, and between pre-DLB and pre-PD patients. This allowed a prediction of the possible future clinical outcome of iRBD patients. We provide evidence of altered lipoprotein and glycosylation profiles in subgroups of iRBD patients. Our results indicate that metabolic alterations and inflammation are involved in iRBD pathophysiology, and suggest biological differences underlying the progression of LTS in iRBD patients. Our data also indicate that profiling of serum samples by NMR may be a useful tool for identifying short-term high-risk iRBD patients for conversion to parkinsonism or dementia., The study was funded by the Fondo de Investigación Sanitaria-Instituto de Salud Carlos III (FIS-ISCIII, Spain)-European Regional Development Fund (FEDER, E.U.) (PI13/01897 to M.V.), Ministerio de Economía y Competitividad (MINECO, Spain) (SAF2015-73997-JIN to A.L. and SAF2016-77541-R to M.V.), Fundació Bancària La Caixa (Junior Leader Fellowship LCF/BQ/PR19/11700005 to A.L. and Health Research Project HR17-00513 to M.V.) and CIBERNED (to M.V. and E.T.). A.L. was the recipient of a postdoctoral contract SAF2015-73997-JIN from MINECO (Spain) with co-funding from FEDER (E.U.) and is currently funded by the Junior Leader Program from Fundació Bancària La Caixa (grant LCF/BQ/PR19/11700005). H.X. is the recipient of a Radboud University Personal Ph.D. Grant.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Functional Rescue of Dopaminergic Neuron Loss in Parkinson's Disease Mice After Transplantation of Hematopoietic Stem and Progenitor Cells

  • Altarche-Xifro, Wassim
  • di Vicino, Umberto
  • Muñoz-Martin, Maria Isabel
  • Bortolozzi, Analía|||0000-0002-2069-9192
  • Bové, Jordi|||0000-0002-2529-205X
  • Vila Bover, Miquel|||0000-0002-1352-989X
  • Cosma, Maria Pia
Parkinson's disease is a common neurodegenerative disorder, which is due to the loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc) and for which no definitive cure is currently available. Cellular functions in mouse and human tissues can be restored after fusion of bone marrow (BM)-derived cells with a variety of somatic cells. Here, after transplantation of hematopoietic stem and progenitor cells (HSPCs) in the SNpc of two different mouse models of Parkinson's disease, we significantly ameliorated the dopaminergic neuron loss and function. We show fusion of transplanted HSPCs with neurons and with glial cells in the ventral midbrain of Parkinson's disease mice. Interestingly, the hybrids can undergo reprogramming in vivo and survived up to 4 weeks after transplantation, while acquiring features of mature astroglia. These newly generated astroglia produced Wnt1 and were essential for functional rescue of the dopaminergic neurons. Our data suggest that glial-derived hybrids produced upon fusion of transplanted HSPCs in the SNpc can rescue the Parkinson's disease phenotype via a niche-mediated effect, and can be exploited as an efficient cell-therapy approach. A definitive therapy for Parkinson's disease is not available. Here, we transplanted hematopoietic stem and progenitor cells into the substantia nigra of brains of two different mouse models of Parkinson's disease. These transplanted cells fused with neurons and glial cells of the recipient mice. Four weeks after transplantation, the hybrids acquired features of mature astroglia, secreted Wnt1, and functionally ameliorated dopaminergic neuron loss. Current cell therapy approaches are being pursued in the striatum with the aim to increase dopamine levels. Here we show that the loss of dopaminergic neurons can be protected against by direct actions in the substantia nigra.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Lack of pathogenic potential of peripheral α-synuclein aggregates from Parkinson's disease patients

  • Recasens, Ariadna
  • Carballo-Carbajal, Iria|||0000-0002-4403-8006
  • Parent, Annabelle|||0000-0002-6195-812X
  • Bové, Jordi|||0000-0002-2529-205X
  • Gelpi, Ellen|||0000-0003-2948-4187
  • Tolosa, Eduardo
  • Vila Bover, Miquel|||0000-0002-1352-989X
The online version of this article (10.1186/s40478-018-0509-1) contains supplementary material, which is available to authorized users.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Mitochondrial Quality Control in Neurodegenerative Diseases, Focus on Parkinson's Disease and Huntington's Disease

  • Franco Iborra, Sandra|||0000-0001-7385-657X
  • Vila Bover, Miquel|||0000-0002-1352-989X
  • Perier, Celine|||0000-0001-7446-8173
In recent years, several important advances have been made in our understanding of the pathways that lead to cell dysfunction and death in Parkinson's disease (PD) and Huntington's disease (HD). Despite distinct clinical and pathological features, these two neurodegenerative diseases share critical processes, such as the presence of misfolded and/or aggregated proteins, oxidative stress, and mitochondrial anomalies. Even though the mitochondria are commonly regarded as the "powerhouses" of the cell, they are involved in a multitude of cellular events such as heme metabolism, calcium homeostasis, and apoptosis. Disruption of mitochondrial homeostasis and subsequent mitochondrial dysfunction play a key role in the pathophysiology of neurodegenerative diseases, further highlighting the importance of these organelles, especially in neurons. The maintenance of mitochondrial integrity through different surveillance mechanisms is thus critical for neuron survival. Mitochondria display a wide range of quality control mechanisms, from the molecular to the organellar level. Interestingly, many of these lines of defense have been found to be altered in neurodegenerative diseases such as PD and HD. Current knowledge and further elucidation of the novel pathways that protect the cell through mitochondrial quality control may offer unique opportunities for disease therapy in situations where ongoing mitochondrial damage occurs. In this review, we discuss the involvement of mitochondrial dysfunction in neurodegeneration with a special focus on the recent findings regarding mitochondrial quality control pathways, beyond the classical effects of increased production of reactive oxygen species (ROS) and bioenergetic alterations. We also discuss how disturbances in these processes underlie the pathophysiology of neurodegenerative disorders such as PD and HD.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Brain tyrosinase overexpression implicates age-dependent neuromelanin production in Parkinson's disease pathogenesis

  • Carballo-Carbajal, Iria|||0000-0002-4403-8006
  • Laguna, Ariadna|||0000-0002-9732-6677
  • Romero-Giménez, Jordi|||0000-0002-8459-9895
  • Cuadros, Thais|||0000-0001-6994-2424
  • Bové, Jordi|||0000-0002-2529-205X
  • Martinez-Vicente, Marta|||0000-0001-7053-2625
  • Parent, Annabelle|||0000-0002-6195-812X
  • González Sepúlveda, Marta|||0000-0002-5627-847X
  • Peñuelas, Núria|||0000-0001-6443-9790
  • Torra, Albert|||0000-0002-6852-7146
  • Rodríguez-Galván, Beatriz
  • Ballabio, Andrea|||0000-0003-1381-4604
  • Hasegawa, Takafumi
  • Bortolozzi, Analía|||0000-0002-2069-9192
  • Gelpi, Ellen|||0000-0003-2948-4187
  • Vila Bover, Miquel|||0000-0002-1352-989X
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Serum metabolic biomarkers for synucleinopathy conversion in isolated REM sleep behavior disorder

  • Laguna, Ariadna|||0000-0002-9732-6677
  • Xicoy, Helena|||0000-0001-6641-1222
  • Tolosa, Eduardo
  • Serradell, Mònica|||0000-0002-2954-3020
  • Vilas Rolán, Dolores|||0000-0003-3084-053X
  • Gaig, Carles|||0000-0002-7113-8125
  • Fernández, Manel
  • Yanes, Oscar|||0000-0003-3695-7157
  • Santamaria Cano, Joan|||0000-0003-0879-4135
  • Amigó, Núria|||0000-0002-0116-9145
  • Iranzo, Alex|||0000-0002-5618-8271
  • Vila Bover, Miquel|||0000-0002-1352-989X
Isolated rapid eye movement (REM) sleep behavior disorder (iRBD) is a prodromal stage of Lewy-type synucleinopathies (LTS), which can present either with an initial predominant parkinsonism (Parkinson's disease (PD)) or dementia (dementia with Lewy bodies (DLB)). To provide insights into the underlying pathogenic mechanisms, the lipoprotein and protein glycosylation profile of 82 iRBD patients, collected before and/or after their conversion to an overt LTS, and 29 matched control serum samples were assessed by nuclear magnetic resonance (NMR) spectroscopy. Data were statistically analyzed to identify altered metabolites and construct predictive models. Univariant analysis detected no differences between iRBD patients with an LTS compared to controls. However, significant differences were found when the analysis distinguished between iRBD patients that manifested initially predominant parkinsonism (pre-PD) or dementia (pre-DLB). Significant differences were also found in the analysis of paired iRBD samples pre- and post-LTS diagnosis. Predictive models were built and distinguished between controls and pre-DLB patients, and between pre-DLB and pre-PD patients. This allowed a prediction of the possible future clinical outcome of iRBD patients. We provide evidence of altered lipoprotein and glycosylation profiles in subgroups of iRBD patients. Our results indicate that metabolic alterations and inflammation are involved in iRBD pathophysiology, and suggest biological differences underlying the progression of LTS in iRBD patients. Our data also indicate that profiling of serum samples by NMR may be a useful tool for identifying short-term high-risk iRBD patients for conversion to parkinsonism or dementia.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Serum metabolic biomarkers for synucleinopathy conversion in isolated REM sleep behavior disorder

  • Xicoy Cortada, Helena
  • Tolosa, Eduardo
  • Serradell, Mònica
  • Gaig, Carles
  • Vila Bover, Miquel
  • Laguna Tuset, Ariadna
  • Vilas, Dolores
Neurodegeneració; Malaltia de Parkinson; Marcadors predictius, Neurodegeneración; Enfermedad de Parkinson; Marcadores predictivos, Neurodegeneration; Parkinson's disease; Predictive markers, Isolated rapid eye movement (REM) sleep behavior disorder (iRBD) is a prodromal stage of Lewy-type synucleinopathies (LTS), which can present either with an initial predominant parkinsonism (Parkinson’s disease (PD)) or dementia (dementia with Lewy bodies (DLB)). To provide insights into the underlying pathogenic mechanisms, the lipoprotein and protein glycosylation profile of 82 iRBD patients, collected before and/or after their conversion to an overt LTS, and 29 matched control serum samples were assessed by nuclear magnetic resonance (NMR) spectroscopy. Data were statistically analyzed to identify altered metabolites and construct predictive models. Univariant analysis detected no differences between iRBD patients with an LTS compared to controls. However, significant differences were found when the analysis distinguished between iRBD patients that manifested initially predominant parkinsonism (pre-PD) or dementia (pre-DLB). Significant differences were also found in the analysis of paired iRBD samples pre- and post-LTS diagnosis. Predictive models were built and distinguished between controls and pre-DLB patients, and between pre-DLB and pre-PD patients. This allowed a prediction of the possible future clinical outcome of iRBD patients. We provide evidence of altered lipoprotein and glycosylation profiles in subgroups of iRBD patients. Our results indicate that metabolic alterations and inflammation are involved in iRBD pathophysiology, and suggest biological differences underlying the progression of LTS in iRBD patients. Our data also indicate that profiling of serum samples by NMR may be a useful tool for identifying short-term high-risk iRBD patients for conversion to parkinsonism or dementia., The study was funded by the Fondo de Investigación Sanitaria-Instituto de Salud Carlos III (FIS-ISCIII, Spain)-European Regional Development Fund (FEDER, E.U.) (PI13/01897 to M.V.), Ministerio de Economía y Competitividad (MINECO, Spain) (SAF2015-73997-JIN to A.L. and SAF2016-77541-R to M.V.), Fundació Bancària La Caixa (Junior Leader Fellowship LCF/BQ/PR19/11700005 to A.L. and Health Research Project HR17-00513 to M.V.) and CIBERNED (to M.V. and E.T.). A.L. was the recipient of a postdoctoral contract SAF2015-73997-JIN from MINECO (Spain) with co-funding from FEDER (E.U.) and is currently funded by the Junior Leader Program from Fundació Bancària La Caixa (grant LCF/BQ/PR19/11700005). H.X. is the recipient of a Radboud University Personal Ph.D. Grant.